Hammered by critics, NewLink strikes back with positive PhII indoximod data — and shares rocket up
Few biotechs have inspired the kind of love-hate relationship that NewLink Genetics $NLNK seems to provoke among the bulls and bears in the biotech investment community following its IDO work with passionate self-interest.
Earlier this year, the sentiment ran distinctly along the bear/hate argument, born out by some disappointing data and Genentech’s decision to punt their partnered IDO1 therapy. It also didn’t help that their cancer vaccine flopped badly in 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.